<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598806</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-612</org_study_id>
    <nct_id>NCT00598806</nct_id>
  </id_info>
  <brief_title>Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (Protocol SPI-612)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in
      randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of
      Bladder Tumor (TURBT) plus apaziquone versus those who received TURBT plus placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study. Within
      14 days of Screening, eligible patients underwent a TURBT during Visit 1 (Day 0) following
      which they were immediately randomized in a 1:1 ratio to receive either placebo or 4 mg
      apaziquone, instilled in a volume of 40 mL into the bladder within 6 hours from the end of
      the TURBT procedure. After a 60-minute retention period, study drug was drained from the
      bladder.

      A postoperative follow-up examination and review of the local pathology report were performed
      at Visit 2, which occurred 21 days (±10 days) after the TURBT (Week 3).

        -  If the histology of the patient's tumor was confirmed as Ta, G1-G2 (ie, low grade
           according to World Health Organization [WHO]/International Society of Urologic Pathology
           [ISUP] classification), no further treatment was given and the patient was observed
           cystoscopically every 3 months through Year 2 for tumor recurrence (Visit 3 through
           Visit 10).

        -  If the histology of the patient's tumor was other than Ta, G1 or G2 (low grade [WHO/ISUP
           classification]), further treatment was given in accordance with current treatment
           guidelines, and the patient was followed up cystoscopically every 3 months through Year
           2 for tumor recurrence (Visit 3 through Visit 10).

      All patients were to be followed for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence Rate at 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of participants with histologically confirmed recurrence of the bladder tumor at any time after randomization and on or before year 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrence</measure>
    <time_frame>2 years</time_frame>
    <description>The number of months from randomization to histologically confirmed recurrence of the patient's bladder tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Rate at 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of participants that progress to either a higher stage or grade from the histologically confirmed stage and grade at time of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>2 years</time_frame>
    <description>The number of months from randomization to progression to either a higher stage or grade of the patient's bladder tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Recurrences Per Patient</measure>
    <time_frame>2 years</time_frame>
    <description>The number of histologically confirmed recurrences during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Interval</measure>
    <time_frame>2 years</time_frame>
    <description>The number of months from randomization to histologically confirmed progression of the patient's bladder tumor or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>The number of months from randomization to histologically confirmed recurrence of the patient's bladder tumor or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>The number of months from randomization to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">812</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Apaziquone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apaziquone</intervention_name>
    <description>A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT</description>
    <arm_group_label>Apaziquone</arm_group_label>
    <other_name>EOquin®, Qapzola</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single intravesical dose of placebo instilled into the bladder post-TURBT</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TURBT</intervention_name>
    <description>TransUrethral Resection of the Bladder Tumor</description>
    <arm_group_label>Apaziquone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All of the following questions must be answered &quot;Yes&quot; in order for the patient to
        participate in the study.

          1. Has the patient given written informed consent?

          2. Is the patient at least 18 years old?

          3. Does the patient have transitional cell carcinoma of the bladder with clinically
             apparent tumor Ta, grade G1-G2?

          4. If the patient is a female of childbearing potential, is she using an
             acceptable/effective method of contraception?

          5. If the patient is a female of childbearing potential, has she had a negative serum
             pregnancy test within the past 14 days?

          6. Is the patient willing and able to abide by the protocol?

        Exclusion Criteria:

        All of the following questions must be answered &quot;No&quot; in order for the patient to
        participate in the study.

          1. Does the patient have more than 5 bladder tumors?

          2. Does any single bladder tumor exceed 3.5 cm in diameter?

          3. Does the patient have a single, primary bladder tumor &lt;0.5 cm and has no previous
             diagnosis of bladder cancer?

          4. Has the patient ever received EOquin(r)?

          5. Does the patient have, or has the patient ever had, any bladder tumor known to be
             other than tumor Ta or grade G1 or G2 (low grade [WHO/ISUP classification])?

          6. Does the patient have, or has the patient ever had any bladder tumor with histology
             other than transitional cell carcinoma?

          7. Does the patient have, or has the patient ever had, carcinoma in situ (CIS)?

          8. Does the patient have an active urinary tract infection?

          9. Does the patient have a bleeding disorder or a screening platelet count &lt; 100 x 109/L?

         10. Does the patient have any unstable medical condition that would make it unsafe for
             him/her to undergo TURBT under general or spinal anesthesia?

         11. Does the patient have screening hemoglobin &lt; 10 mg/dL, a screening absolute neutrophil
             count &lt; 1.5 x 109/L?

         12. Does the patient have a known immunodeficiency disorder?

         13. Has the patient received any investigational treatment within the past 30 days?

         14. Is the patient breast feeding?

         15. Does the patient have a history of interstitial cystitis?

         16. Does the patient have a history of allergy to red color food dye?

         17. Has the patient had transitional cell carcinoma of the bladder within the past 4
             months?
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shanta Chawla, MD</last_name>
    <role>Study Director</role>
    <affiliation>Spectrum Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Urology Medical Center Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hal J. Bashein, D.O.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Enterprises</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Fulton Urology</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hines VA Hospital</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Center</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmaTrials, Inc. - Male &amp; Female Urology</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmaTrials, Inc.</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Clinical Research Associates, LLC</name>
      <address>
        <city>Bay Shore</city>
        <state>New York</state>
        <zip>11706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates, PC</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore - LIJ Health System - The Arthur Smith Institute for Urology</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Urology Specialists</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Urologic Care</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina, Dept. of Urology</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates of South Texas</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salt Lake Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult and Pediatric Urologists</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prostate Cancer Institute</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V4R6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lintor Medical, Inc.</name>
      <address>
        <city>North Vancouver</city>
        <state>British Columbia</state>
        <zip>V7L2P7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andreou Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V1N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Can-Med Clinical Research, Inc</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G. Steinhoff Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Male/Female Health and Research Center - Royal Court Medical Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brantford Urology Research</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <zip>N3R4N3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G. Kenneth Jansz Medicine Professional Corporation</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Resource Centre</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7S1V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital / Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates, Urologic Medical Research</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2N2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mor Urology, Inc.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3X1W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Bernard Goldfarb</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanley Flax Medical Professional Corporation</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3B3S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fe/Male Health Centre</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orillia Urology Associates</name>
      <address>
        <city>Orillia</city>
        <state>Ontario</state>
        <zip>L3V7V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urotec</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H7K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ADA Medical Ltd.</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J7B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AGT Research</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1P2T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology &amp; Male Infertility</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1S4V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto East General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C5T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Male Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A3B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Health Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6S4W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UroLaval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7G2E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Urology Associates</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultra-Med, Inc.</name>
      <address>
        <city>Pointe Clare</city>
        <state>Quebec</state>
        <zip>H9R4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1R3S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny</name>
      <address>
        <city>Białystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki w Bielsku-Białej</name>
      <address>
        <city>Bielsko-Biała</city>
        <zip>43-316</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademickie Centrum Kliniczne - Szpital Akademii Medycznej w Gdańsku</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Publiczny Specjalistyczny Zakład Opieki Zdrowotnej w Inowrocławiu</name>
      <address>
        <city>Inowrocław</city>
        <zip>88-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Miejski im. Prof. E. Michałowskiego</name>
      <address>
        <city>Katowice</city>
        <zip>40-073</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Świętokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakład Opieki Zdrowotnej</name>
      <address>
        <city>Kielce</city>
        <zip>25-734</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Kościerzynie</name>
      <address>
        <city>Kościerzyna</city>
        <zip>83-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej &quot;Racławicka&quot;</name>
      <address>
        <city>Kraków</city>
        <zip>30-017</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakład Opieki Zdrowotnej w Pabianicach</name>
      <address>
        <city>Pabianice</city>
        <zip>95-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zakład Opieki Zdrowotnej Poznań - Stare Miasto</name>
      <address>
        <city>Poznań</city>
        <zip>61-285</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kolejowy im. Dr med.. Włodzimierza Roeflera w Pruszkowie</name>
      <address>
        <city>Pruszków</city>
        <zip>05-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakład Opieki Zdrowotnej, Wojewódzki Szpital Specjalistyczny nr 3</name>
      <address>
        <city>Rybnik</city>
        <zip>44-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny W Siedlcach</name>
      <address>
        <city>Siedlce</city>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pomorska Akademia Medyczna</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny im Janusza Korczaka</name>
      <address>
        <city>Słupsk</city>
        <zip>76-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medycznego Kształcenia Podyplomowego, Samodzielny Publiczny Szpital Kliniczny im. Prof. W. Orłowskiego</name>
      <address>
        <city>Warszawa</city>
        <zip>00-416</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny, Centralny Szpital Kliniczny MON</name>
      <address>
        <city>Warszawa</city>
        <zip>00-909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Dzieciątka Jezus - Centrum Leczenia Obrażeń</name>
      <address>
        <city>Warszawa</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii im. Marii Skodowskiej-Curie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacja &quot;Urologia&quot;, Międzyleski Szpital Specjalistyczny w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademicki Szpital Kliniczny im Jana Mikulicza-Radeckiego we Wrocławiu</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny we Wrocławiu, Ośrodek Badawczo Rozwojowy</name>
      <address>
        <city>Wrocław</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny nr 2 Wojskowej Akademii Medycznej Uniwersytetu Medycznego w Łodzi - Centralny Szpital Weteranów</name>
      <address>
        <city>Łódź</city>
        <zip>90-549</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2008</study_first_posted>
  <results_first_submitted>July 14, 2017</results_first_submitted>
  <results_first_submitted_qc>July 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 15, 2017</results_first_posted>
  <disposition_first_submitted>December 18, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 26, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 19, 2015</disposition_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Noninvasive Bladder Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apaziquone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Apaziquone</title>
          <description>Apaziquone: TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="402"/>
                <participants group_id="P2" count="410"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="329"/>
                <participants group_id="P2" count="346"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Apaziquone</title>
          <description>Apaziquone: TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="402"/>
            <count group_id="B2" value="410"/>
            <count group_id="B3" value="812"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.9" spread="11.60"/>
                    <measurement group_id="B2" value="66.5" spread="11.83"/>
                    <measurement group_id="B3" value="66.7" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="213"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="389"/>
                    <measurement group_id="B2" value="398"/>
                    <measurement group_id="B3" value="787"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="392"/>
                    <measurement group_id="B2" value="400"/>
                    <measurement group_id="B3" value="792"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrence Rate at 2 Years</title>
        <description>The percentage of participants with histologically confirmed recurrence of the bladder tumor at any time after randomization and on or before year 2.</description>
        <time_frame>2 years</time_frame>
        <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Apaziquone</title>
            <description>Apaziquone: TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Rate at 2 Years</title>
          <description>The percentage of participants with histologically confirmed recurrence of the bladder tumor at any time after randomization and on or before year 2.</description>
          <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Recurrence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Recurrence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1094</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recurrence</title>
        <description>The number of months from randomization to histologically confirmed recurrence of the patient’s bladder tumor.</description>
        <time_frame>2 years</time_frame>
        <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Apaziquone</title>
            <description>Apaziquone: TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recurrence</title>
          <description>The number of months from randomization to histologically confirmed recurrence of the patient’s bladder tumor.</description>
          <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" spread="0.5"/>
                    <measurement group_id="O2" value="16.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1038</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Rate at 2 Years</title>
        <description>The percentage of participants that progress to either a higher stage or grade from the histologically confirmed stage and grade at time of randomization.</description>
        <time_frame>2 years</time_frame>
        <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Apaziquone</title>
            <description>Apaziquone: TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Rate at 2 Years</title>
          <description>The percentage of participants that progress to either a higher stage or grade from the histologically confirmed stage and grade at time of randomization.</description>
          <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Progression</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Progression</title>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>The number of months from randomization to progression to either a higher stage or grade of the patient’s bladder tumor.</description>
        <time_frame>2 years</time_frame>
        <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Apaziquone</title>
            <description>Apaziquone: TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>The number of months from randomization to progression to either a higher stage or grade of the patient’s bladder tumor.</description>
          <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="0.3"/>
                    <measurement group_id="O2" value="21.9" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Recurrences Per Patient</title>
        <description>The number of histologically confirmed recurrences during the course of the study.</description>
        <time_frame>2 years</time_frame>
        <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Apaziquone</title>
            <description>Apaziquone: TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Recurrences Per Patient</title>
          <description>The number of histologically confirmed recurrences during the course of the study.</description>
          <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
          <units>recurrences</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.98"/>
                    <measurement group_id="O2" value="0.9" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-Free Interval</title>
        <description>The number of months from randomization to histologically confirmed progression of the patient’s bladder tumor or death from any cause</description>
        <time_frame>2 years</time_frame>
        <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Apaziquone</title>
            <description>Apaziquone: TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-Free Interval</title>
          <description>The number of months from randomization to histologically confirmed progression of the patient’s bladder tumor or death from any cause</description>
          <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="0.3"/>
                    <measurement group_id="O2" value="21.9" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-Free Survival</title>
        <description>The number of months from randomization to histologically confirmed recurrence of the patient’s bladder tumor or death from any cause</description>
        <time_frame>2 years</time_frame>
        <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Apaziquone</title>
            <description>Apaziquone: TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-Free Survival</title>
          <description>The number of months from randomization to histologically confirmed recurrence of the patient’s bladder tumor or death from any cause</description>
          <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="0.5"/>
                    <measurement group_id="O2" value="16.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The number of months from randomization to death from any cause.</description>
        <time_frame>2 years</time_frame>
        <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Apaziquone</title>
            <description>Apaziquone: TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The number of months from randomization to death from any cause.</description>
          <population>Target Ta, G1-G2 Population: patients who had 4 or fewer tumors that were ≤ 3.5 cm each at the time of randomization and who had subsequent histological confirmation from the central pathology lab that the tumors resected at the time of randomization were Ta, Grade 1 or 2.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="0.14"/>
                    <measurement group_id="O2" value="20.2" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent Adverse Events (ie, AEs that occurred or worsened following the TURBT procedure) were recorded from the time of randomization to Month 6; after Month 6 until Month 24 (end of study), only genitourinary AEs and Serious AEs (SAEs) were recorded.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Apaziquone</title>
          <description>Apaziquone: TURBT + a single intravesical dose of EOquin® 4mg in 40ml instilled into the bladder post-TURBT</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Gastric ulcer hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Intestinal strangulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Implant site erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Infusion site thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Ascariasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Post procedural hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Urinary retention postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Urine cytology abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Hypovolemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Transitional cell cancer of the renal pelvis and ureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Urinary bladder hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Urethral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Hemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm repair</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Radiotherapy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Radical prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cystocele repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Arterial aneurysm repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Carotid endarterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Urethral operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Urethrotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Bladder irrigation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Hemorrhoid operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Radical mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Ureteric calculus removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Urinary cystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="313" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="322" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>First publication is the multi-center publication of Study results from all study sites. Other than the multi-center publication, site may publish an independent publication of data generated by site subject to Sponsor review rights (e.g., review for intellectual property, confidentiality).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gajanan Bhat, PhD</name_or_title>
      <organization>Spectrum Pharmaceuticals</organization>
      <phone>949-743-9219</phone>
      <email>Gajanan.Bhat@sppirx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

